HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B study

This article was originally published in The Tan Sheet

Executive Summary

While emergency contraception use was higher among women given an advance supply of birth control pills, it did not result in a lower pregnancy rate compared to those not provided an advance supply, according to a review published in the most recent issue of The Cochrane Library. The review evaluated eight studies of more than 6,000 women in the U.S., India and China. "Even though advance provision increased use, we don't know if women were using EC at the times when they were at risk for pregnancy, when it was really needed," according to lead reviewer Chelsea Polis. Additionally, the review found there was no difference in sexually transmitted infection rates between the two groups, thus "advance provision of EC has no harmful effects in terms of risky sexual behaviors." In September 2006 Barr announced plans to track whether its Plan B EC is being used in place of other forms of contraception (1"The Tan Sheet" Sept. 4, 2006, p. 5)...

You may also be interested in...



Barr Takes CARE To Monitor Plan B Consumer Behavior Trends

Barr plans to track whether Plan B is being used in lieu of other forms of contraception under its Convenient Access Responsible Education (CARE) postmarketing program

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Keeping Track: Two Targeted Oncologics And A Novel SGLT-2 Inhibitor Clear US FDA

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138714

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel